Prevention of hepatitis B recurrence in liver transplant patients using oral antiviral therapy without long-term hepatitis B immunoglobulin

Joseph Ahn, Stanley Martin Cohen

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Small studies have suggested that nucleos(t)ide analogue therapy (NAT) with reduced hepatitis B immunoglobulin (HBIG) duration may be efficacious in preventing post-liver transplantation (LT) HBV recurrence. This larger study evaluates the use of NAT with short term (<6 mo) or no HBIG for prevention of post-LT HBV recurrence. Patients and Methods: All HBV patients undergoing LT at a university transplant center between 2002 and 2007 were identified retrospectively. Patient demographics, medication regimen, and adverse events were noted. The primary endpoint was HBV recurrence and secondary endpoints were graft and patient survival. Results: 28 study patients were identified. Of these 28 patients, 4 (14%) received no HBIG, 6 (22%) received only inpatient HBIG, and 18 (64%) received inpatient HBIG and outpatient HBIG. 16 of the 28 patients (57%) received combination NAT and 12 patients (43%) received single NAT. At a median time of 15.5 months (range 9-24 months) post-LT, 4 of the 28 patients (14%) had recurrent HBV. Of those patients with recurrent HBV, 3 received both inpatient and outpatient HBIG and 1 received no HBIG. All cases of HBV recurrence were associated with noncompliance. Conclusions: NAT with short-term or no HBIG was efficacious and safe in preventing post-LT HBV. All compliant patients were HBV-free, including 9 patients who received no HBIG or only inpatient HBIG. Additional studies using NAT without HBIG appear justified.

Original languageEnglish (US)
Pages (from-to)638-645
Number of pages8
JournalHepatitis Monthly
Volume11
Issue number8
DOIs
StatePublished - Aug 2011
Externally publishedYes

Fingerprint

Hepatitis B
Antiviral Agents
Immunoglobulins
Transplants
Recurrence
Liver
Liver Transplantation
Inpatients
Therapeutics
Outpatients
Graft Survival
N-acetyltalosaminuronic acid
Demography

Keywords

  • Hepatitis B
  • Immunoglobulin
  • Liver transplantation

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

Prevention of hepatitis B recurrence in liver transplant patients using oral antiviral therapy without long-term hepatitis B immunoglobulin. / Ahn, Joseph; Cohen, Stanley Martin.

In: Hepatitis Monthly, Vol. 11, No. 8, 08.2011, p. 638-645.

Research output: Contribution to journalArticle

@article{671ab245b47a4f5aa35742804497eaa8,
title = "Prevention of hepatitis B recurrence in liver transplant patients using oral antiviral therapy without long-term hepatitis B immunoglobulin",
abstract = "Background: Small studies have suggested that nucleos(t)ide analogue therapy (NAT) with reduced hepatitis B immunoglobulin (HBIG) duration may be efficacious in preventing post-liver transplantation (LT) HBV recurrence. This larger study evaluates the use of NAT with short term (<6 mo) or no HBIG for prevention of post-LT HBV recurrence. Patients and Methods: All HBV patients undergoing LT at a university transplant center between 2002 and 2007 were identified retrospectively. Patient demographics, medication regimen, and adverse events were noted. The primary endpoint was HBV recurrence and secondary endpoints were graft and patient survival. Results: 28 study patients were identified. Of these 28 patients, 4 (14{\%}) received no HBIG, 6 (22{\%}) received only inpatient HBIG, and 18 (64{\%}) received inpatient HBIG and outpatient HBIG. 16 of the 28 patients (57{\%}) received combination NAT and 12 patients (43{\%}) received single NAT. At a median time of 15.5 months (range 9-24 months) post-LT, 4 of the 28 patients (14{\%}) had recurrent HBV. Of those patients with recurrent HBV, 3 received both inpatient and outpatient HBIG and 1 received no HBIG. All cases of HBV recurrence were associated with noncompliance. Conclusions: NAT with short-term or no HBIG was efficacious and safe in preventing post-LT HBV. All compliant patients were HBV-free, including 9 patients who received no HBIG or only inpatient HBIG. Additional studies using NAT without HBIG appear justified.",
keywords = "Hepatitis B, Immunoglobulin, Liver transplantation",
author = "Joseph Ahn and Cohen, {Stanley Martin}",
year = "2011",
month = "8",
doi = "10.5812/kowsar.1735143X.717",
language = "English (US)",
volume = "11",
pages = "638--645",
journal = "Hepatitis Monthly",
issn = "1735-143X",
publisher = "Kowsar Publishing Company",
number = "8",

}

TY - JOUR

T1 - Prevention of hepatitis B recurrence in liver transplant patients using oral antiviral therapy without long-term hepatitis B immunoglobulin

AU - Ahn, Joseph

AU - Cohen, Stanley Martin

PY - 2011/8

Y1 - 2011/8

N2 - Background: Small studies have suggested that nucleos(t)ide analogue therapy (NAT) with reduced hepatitis B immunoglobulin (HBIG) duration may be efficacious in preventing post-liver transplantation (LT) HBV recurrence. This larger study evaluates the use of NAT with short term (<6 mo) or no HBIG for prevention of post-LT HBV recurrence. Patients and Methods: All HBV patients undergoing LT at a university transplant center between 2002 and 2007 were identified retrospectively. Patient demographics, medication regimen, and adverse events were noted. The primary endpoint was HBV recurrence and secondary endpoints were graft and patient survival. Results: 28 study patients were identified. Of these 28 patients, 4 (14%) received no HBIG, 6 (22%) received only inpatient HBIG, and 18 (64%) received inpatient HBIG and outpatient HBIG. 16 of the 28 patients (57%) received combination NAT and 12 patients (43%) received single NAT. At a median time of 15.5 months (range 9-24 months) post-LT, 4 of the 28 patients (14%) had recurrent HBV. Of those patients with recurrent HBV, 3 received both inpatient and outpatient HBIG and 1 received no HBIG. All cases of HBV recurrence were associated with noncompliance. Conclusions: NAT with short-term or no HBIG was efficacious and safe in preventing post-LT HBV. All compliant patients were HBV-free, including 9 patients who received no HBIG or only inpatient HBIG. Additional studies using NAT without HBIG appear justified.

AB - Background: Small studies have suggested that nucleos(t)ide analogue therapy (NAT) with reduced hepatitis B immunoglobulin (HBIG) duration may be efficacious in preventing post-liver transplantation (LT) HBV recurrence. This larger study evaluates the use of NAT with short term (<6 mo) or no HBIG for prevention of post-LT HBV recurrence. Patients and Methods: All HBV patients undergoing LT at a university transplant center between 2002 and 2007 were identified retrospectively. Patient demographics, medication regimen, and adverse events were noted. The primary endpoint was HBV recurrence and secondary endpoints were graft and patient survival. Results: 28 study patients were identified. Of these 28 patients, 4 (14%) received no HBIG, 6 (22%) received only inpatient HBIG, and 18 (64%) received inpatient HBIG and outpatient HBIG. 16 of the 28 patients (57%) received combination NAT and 12 patients (43%) received single NAT. At a median time of 15.5 months (range 9-24 months) post-LT, 4 of the 28 patients (14%) had recurrent HBV. Of those patients with recurrent HBV, 3 received both inpatient and outpatient HBIG and 1 received no HBIG. All cases of HBV recurrence were associated with noncompliance. Conclusions: NAT with short-term or no HBIG was efficacious and safe in preventing post-LT HBV. All compliant patients were HBV-free, including 9 patients who received no HBIG or only inpatient HBIG. Additional studies using NAT without HBIG appear justified.

KW - Hepatitis B

KW - Immunoglobulin

KW - Liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=80052588678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052588678&partnerID=8YFLogxK

U2 - 10.5812/kowsar.1735143X.717

DO - 10.5812/kowsar.1735143X.717

M3 - Article

C2 - 22140388

AN - SCOPUS:80052588678

VL - 11

SP - 638

EP - 645

JO - Hepatitis Monthly

JF - Hepatitis Monthly

SN - 1735-143X

IS - 8

ER -